Related Experiment Video
Updated: Jan 16, 2026

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
Published on: November 30, 2013
Targeting microRNA-132 protects against kidney fibrosis and restricts myofibroblast differentiation from cells of
Loïs A K van der Pluijm1, Angela Koudijs1, Jacques Mgj Duijs1
1Department of Internal Medicine (Nephrology) and the Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Centre, Leiden, The Netherlands.
Abstract:
Kidney fibrosis represents a central pathophysiological process in the progression of chronic kidney disease to end-stage kidney failure, yet its underlying cellular mechanisms remain incompletely understood. Cells of renin lineage (CoRL) have not only been shown to possess regenerative capacity following injury but may also contribute to fibrotic remodeling. MicroRNA-132 (miR-132), known to regulate both fibrotic signaling and renin synthesis, represents a potential therapeutic target to halt progression of kidney fibrosis. Here, we investigated the role of miR-132 and CoRL in two complementary models of kidney injury-5/6 nephrectomy and bilateral ischemia-reperfusion injury-using renin lineage-tracing mice treated with a miR-132 antimiR or scrambled control. In both models, miR-132 silencing improved renal function and led to a consistent reduction in interstitial fibrosis and myofibroblast accumulation in the kidney. The number of proliferating myofibroblasts also declined, supporting an antiproliferative effect. Podocyte number per glomerulus was significantly higher upon miR-132 silencing, indicating protection from glomerular damage. CoRL-derived podocytes were present in both models, but not affected by miR-132 knockdown, suggesting that the observed podocyte protection primarily results from reduced loss of resident cells. Lineage tracing further confirmed that CoRL contribute directly to the pool of α-smooth muscle actin+ myofibroblasts. Interestingly, miR-132 silencing reduced the number of CoRL-derived myofibroblasts. Together, these findings identify miR-132 as a regulator of fibrotic remodeling and highlight the dual regenerative and fibrogenic potential of CoRL. Pharmacological inhibition of miR-132 may offer a promising approach to preserve kidney function and limiting fibrosis.NEW & NOTEWORTHY This study demonstrates that cells of renin lineage (CoRL) directly contribute to the myofibroblast pool in two distinct models of kidney injury. Silencing of microRNA-132 reduces kidney fibrosis, preserves podocyte number, and attenuates myofibroblast proliferation, including those derived from CoRL. These findings highlight miR-132 as a promising target to curb fibrotic remodeling while preserving renal structure and uncover new insights into the dual regenerative and profibrotic plasticity of CoRL.
Insights
Silencing microRNA-132 (miR-132) reduces kidney fibrosis and preserves podocyte number by inhibiting myofibroblast proliferation, including those from renin lineage cells (CoRL). This highlights miR-132 as a therapeutic target for chronic kidney disease.
Area of Science:
- Nephrology
- Molecular Biology
- Cell Biology
Background:
- Kidney fibrosis is a key driver of chronic kidney disease (CKD) progression.
- Cells of renin lineage (CoRL) exhibit regenerative and fibrotic potential.
- MicroRNA-132 (miR-132) influences fibrotic signaling and renin synthesis.
Purpose of the Study:
- To investigate the role of miR-132 and CoRL in kidney fibrosis.
- To determine if miR-132 inhibition can ameliorate kidney injury and fibrosis.
Main Methods:
- Utilized 5/6 nephrectomy and bilateral ischemia-reperfusion injury models in renin lineage-tracing mice.
- Administered miR-132 antimiR or scrambled control to mice.
- Assessed renal function, fibrosis, myofibroblast accumulation, and podocyte number.
Main Results:
- miR-132 silencing improved renal function and reduced interstitial fibrosis and myofibroblast accumulation.
- Podocyte number was preserved upon miR-132 silencing, indicating protection from glomerular damage.
- CoRL were confirmed to contribute to myofibroblasts, and miR-132 inhibition reduced this contribution.
Conclusions:
- miR-132 inhibition is a promising therapeutic strategy to reduce kidney fibrosis and preserve renal function.
- CoRL possess both regenerative and fibrogenic plasticity.
- Targeting miR-132 offers a novel approach to manage CKD progression.
More Related Videos
07:01Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
08:56Detection of microRNA Expression in Peritoneal Membrane of Rats Using Quantitative Real-time PCR
Published on: June 27, 2017